Physician profile
Matthew Henry Herrmann
NPI 1760918551
$384,423.37
in general payments reported to CMS, 2019-2025
16 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $559 · 2021: $8,440 · 2022: $83K · 2023: $82K · 2024: $74K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199K · Travel and Lodging: $42K · Consulting Fee: $37K · Food and Beverage: $14K · Gift: $176 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,225.00 |
| Travel and Lodging | $41,554.34 |
| Consulting Fee | $36,926.00 |
| Food and Beverage | $13,991.26 |
| Gift | $176.40 |
| Education | $134.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $376,049.46 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $6,970.54 | 2020-2025 | Yeztugo, Biktarvy |
| Emd Serono, INC. | $706.32 | 2020-2025 | Serostim, Serostim |
| Antares Pharma, INC. | $196.97 | 2020 | |
| Merck Sharp & Dohme LLC | $154.32 | 2019-2025 | Capvaxive, Pifeltro |
| Exact Sciences Corporation | $64.66 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $52.86 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $45.31 | 2019 | |
| Glaxosmithkline, LLC. | $35.45 | 2023-2024 | Benlysta |
| Theratechnologies INC. | $27.10 | 2024 | Trogarzo, Egrifta |
| Allergan, INC. | $25.26 | 2019 | |
| Tolmar, INC. | $23.75 | 2025 | Jatenzo |
| Pfizer INC. | $20.63 | 2025 | |
| Abbvie INC. | $20.40 | 2025 | |
| Melinta Therapeutics, LLC | $15.55 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $14.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Herrmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.